SitemapImpressumDatenschutzerklärungdeutschenglish
MHH Logo

Laufende Studien

Hier finden Sie eine Liste aller in unserer Studienambulanz laufenden Studien.

Studienname Beschreibung Status
NEAT 22 cardiovascular risk Dolutegravir (DTG) laufend
GSK 201637 SWORD switching to dolutegravir plus rilpivirine from integrase inhibitor-based therapy laufend
Merck III 1439-018 Phase III, safety and efficacy of Doravirine (MK-1439) versus Darunavir - extension laufend
Prophet pharmacoeconomic study laufend
Latte-2 GSK1265744 plus abacavir/lamivudine laufend
CHIP START Strategic timing of antiretroviral treatment laufend
GSK 201585 ATLAS safety of a two drug regimen of CAB LA + CPV LA compared with maintenance of current ART laufend
GSK 201584 FLAIR long-acting intramuscular Cabotegravir and Rilpivirine laufend
BMS AI468-038 Maturation Inhibitor (MI) Studie, Phase IIb laufend
EuroSIDA New Cohort 10 HIV/HCV co-infected patients laufend
IDEAL Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events beendet
Merck II 1439-007 MK-1439 (NNRTI) Truvada/Sustiva Therapie naiv beendet
MARCH STUDY (Maraviroc Switch collaborative study), University of New South Wales) beendet
PROTEA Protease inhibitor (DRV/rtv) in mono or triple therapy suppressed HIV infected subjects beendet
GSK ING113086 Phase III, GSK1349572 (ING) 50 mg once daily to raltegravir 400 mg twice daily beendet
GSK SPRING-1 Phase II-b Studie mit dem neuen GSK-Integrasehemmer beendet
ECHAM Liver biopsy study beendet
NEAT 001 Open label randomized two year trial comparing two first-line regimens in HIV infected ART naive subjects: darunavir/r+Tenofovir /emtricitabine vs. Darunavir/r+ raltegravir beendet
RKI Inzidenzstudie Untersuchung Risikoverhalten von HIV pos und neg Personen beendet
Jansen Cilag SENSE Phase IIb etravirine 400 mg qd vs efavirenz 600mg qd in combination with background 2 NRTis comparing neuropsychiatric adverse event profile in naïve pts. beendet
TMC 114 Mono Open-label DRV/r 800/100 QD vs triple combination DRV/r beendet
VIRO VIR-576 Phase 1/II Dose escalation study beendet
Studie BI 1100.1526 Nevirapine ER gegen Nevirapine IR, Randomisierung 2:1 beendet
Boehringer Ingelheim Nevirapine extended release 300mg oder 400mg QD im Vergleich zu 200 mg instant release BID in combination with standard background regimen beendet
TMC 278 C 222 Double blind TMC278 75 mg QD vs Efavirenz 600 mg QD in combination with abacavir und lamivudine beendet
Gilead Elvitegravir/Cobicistat/FTC/TDF Single tablet beendet
GSK Zoster 015 I/IIa safety and immunogenicity of GSK herpes zoster vaccine gE/AS01B /Placebo/ 3 doses beendet